Huisheng oral liquid combined with TACE for treatment of primary hepatic carcinoma: Meta-analysis / 中国介入影像与治疗学

ABSTRACT

Objective: To evaluate the efficacy of Huisheng oral liquid combined with TACE for treatment of primary hepatic carcinoma (PHC) with meta-analysis. Methods: Literature on the treatment of PHC with Huisheng oral liquid combined with TACE in CNKI, Wanfang, VIP, Pubmed, EMbase and Cochrane Library were searched from the establishment of database to October 2018. Meta-analysis of the included articles was performed using Stata 15.0 software. Results: Eight literature were enrolled, including 535 patients with intermediate stage PHC, of which 270 patients were treated with Huisheng oral liquid combined with TACE (study group) and 265 patients were treated with TACE alone (control group). The objective response ratio (risk ratio [RR]=1.39, 95%CI [1.19, 1.63], P<0.01), disease control ratio (RR=1.13, 95%CI [1.04, 1.23], P<0.01) and improvement of Karnofsky performance status score (RR=1.64, 95%CI [1.36, 1.98], P<0.01) were all improved in study group. Conclusion: Huisheng oral liquid combined with TACE is effective and safe for treatment of PHC.